Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. by Lorente, D et al.
ORIGINAL ARTICLE
Circulating tumour cell increase as a biomarker of
disease progression in metastatic castration-resistant
prostate cancer patients with low baseline CTC
counts
D. Lorente1,2, D. Olmos3, J. Mateo2,4, D. Dolling2, D. Bianchini2, G. Seed2, P. Flohr2, M. Crespo2,
I. Figueiredo2, S. Miranda2, H. I. Scher5, L. W. M. M. Terstappen6 & J. S. de Bono2*
1Medical Oncology Service, Hospital La Fe, Valencia, Spain; 2Prostate Cancer Targeted Therapy Group, The Royal Marsden NHS Foundation Trust and The Institute
of Cancer Research, Sutton, Surrey; 3Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; 4Prostate Cancer
Translational Research Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; 5Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial
Sloan Kettering Cancer Center, New York, USA; 6MIRA Research Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede,
The Netherlands
*Correspondence to: Prof. Johann de Bono, Prostate Cancer Targeted Therapy Group, Royal Marsden NHS Foundation Trust, Section of Medicine, The Institute of Cancer
Research, Downs Road, Sutton, Surrey SM2 5PT, UK. Tel: þ44 2087224029; E-mail: johann.de-Bono@icr.ac.uk
Background: The development of treatment response and surrogate biomarkers for advanced prostate cancer care is an unmet
clinical need. Patients with baseline circulating tumour cell (BLCTCs) counts<5/7.5mL represent a good prognosis subgroup but
are non-evaluable for response assessment (decrease in CTCs). The aim of the study is to determine the value of any increase in
CTCs (CTC progression) as an indicator of progression in prostate cancer patients with low pre-treatment CTCs (<5).
Patients and methods: We carried out a post hoc analysis of patients with BLCTCs< 5 treated in the COU-AA-301 (abiraterone or
placeboþ prednisone) and IMMC-38 (chemotherapy) trials. The association of CTC progression (increase in CTCs at 4, 8 or 12weeks)
with overall survival (OS) was evaluated in multi-variable Cox regression models. Performance of survival models with and without
CTC progression was evaluated by calculating ROC curve area under the curves (AUCs) and weighted c-indices.
Results: Overall, 511 patients with CTCs< 5 (421 in COU-AA-301 and 90 in IMMC-38) were selected; 212 (41.7%) had CTC
progression at 4, 8 or 12weeks after treatment initiation. CTC progression was associated with significantly worse OS [27.1
versus 15.1 m; hazard ratio (HR) 3.4 (95% confidence interval [CI] 2.5–4.5; P< 0.001)], independent of baseline CTCs and
established clinical variables. Adding CTC progression to the OS model significantly improved ROC AUC (0.77 versus 0.66;
P< 0.001). Models including CTC progression had superior ROC AUC (0.77 versus 0.69; P< 0.001) and weighted c-index [0.750
versus 0.705; delta c-index: 0.045 (95% CI 0.019–0.071)] values than those including CTC conversion (increase to CTCs 5). In
COU-AA-301, the impact of CTC progression was independent of treatment arm.
Conclusions: Increasing CTCs during the first 12 weeks of treatment are independently associated with worse OS from
advanced prostate cancer in patients with baseline CTCs< 5 treated with abiraterone or chemotherapy and improve models
with established prognostic variables. These findings must be prospectively validated.
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chemotherapy
Introduction
Advanced prostate cancer is a major cause of cancer morbidity
and mortality. In the past decade, several drug development
breakthroughs have greatly increased the therapeutic armament-
arium, improving outcomes from this lethal disease [1]. Despite
this, resistance eventually occurs and the prognosis remains, in fit
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patients, approximately 34 and 58months, respectively, for
metastatic castration-resistant and metastatic non-castrate
disease [1].
Determining response to treatment continues to represent one
of the greatest challenges in advanced prostate cancer care.
Prostate Cancer Working Group (PCWG) 3 guidelines, which
summarize recommendations for outcome assessment of
patients treated within clinical trials, have incorporated circulat-
ing tumour cell (CTC) enumeration as an end point in clinical
trials [2]. Outside clinical trials, however, treatment response as-
sessment continues to rely on prostate-specific antigen (PSA),
bone scintigraphy (BS) and computed tomography, which have
important limitations. Neither PSA nor bone scans allow early
evaluation of disease progression. For instance, PCWG3 recom-
mend that rising PSA values before 12weeks not be considered
progression [2]; similarly, progression by bone scintigraphy
cannot be determined before at least 12–16weeks of treatment
due to the potential for spurious, ‘flare reactions’ [2, 3].
Furthermore, neither BS nor PSA response are established surro-
gates of survival [4].
A significant number of patients have exclusively bone disease
for much of their disease course, which is not amenable to evalu-
ation by RECIST [5]. Furthermore, currently available bio-
markers for advanced prostate cancer treatment response
assessment are not consistently utilized in daily clinical practice,
with many physicians continuing to rely on highly subjective
‘clinical progression’ to discontinue treatment [6]. Delays in
identifying progressive disease lead to overtreatment with inef-
fective agents, and arguably tomore patients experiencing clinical
deterioration on progression.
The enumeration of circulating tumour cell counts (CTCs) has
emerged as a powerful biomarker for the assessment of prognosis
and response to treatment. A baseline CTC count 5/7.5ml has
been consistently associated with worse outcome across large,
randomized clinical trials [7–9]. Furthermore, the assessment of
a composite biomarker [CTCs and lactate dehydrogenase
(LDH)] after 12 weeks of treatment has been shown to be a surro-
gate of survival at the individual-patient level [9].
A number of studies have also evaluated the value of CTC enu-
meration as a response biomarker, that is, the association of
changes in CTCs during treatment with outcome. In patients
with unfavourable (5 CTCs/7.5ml) counts, a decline in CTCs
has been associated with improved outcomes and response to
treatment in patients treated with both chemotherapy and hor-
mone therapy [10]. Furthermore, CTC enumeration has proven
to be a more powerful biomarker than PSA [11]. PCWG3 recom-
mendations now include CTC enumeration for the assessment of
patients in clinical trials.
Patients with favourable (<5 CTCs/7.5mL) baseline counts
represent a subgroup of patients with a significantly better
prognosis. These patients, especially those with undetectable
CTCs at baseline, are not evaluable for response. Monitoring
CTC counts in these patients can enable the detection of ‘CTC
progression’, which has been evaluated as either a ‘conversion’
to unfavourable CTC counts [12, 13] or as any increase in CTC
numbers.
We have previously reported the association of 30% CTC falls
with improved outcome in patients with unfavourable (5
CTCs/7.5ml) baseline CTCs [10]. In the present study, we aimed
to analyse the value of CTC increases in patients with low (< 5
CTCs/7.5ml) baseline CTCs participating in the prospective
COU-AA-301 and IMMC-38 trials.
Methods
Study population and procedures
We report an unplanned post hoc analysis of the COU-AA-301 and
IMMC-38 trials, both of which have been published previously [12, 14].
The phase III COU-AA-301 trial compared abiraterone and prednisone
with placebo with prednisone in metastatic castration-resistant prostate
cancer (mCRPC) patients previously treated with chemotherapy.
IMMC-38 was a prospective, open-label study in patients with mCRPC
undergoing treatment with chemotherapy (70% of patients receiving
docetaxel) as first, second or third line [12]. CTCs were collected at base-
line, cycle 2 day 1 (weeks 4–5), cycle 3 day 1 (weeks 8–9) and cycle 4 day 1
(weeks 12–13) in COU-AA-301. In IMMC-38, CTCs were evaluated
at weeks 2–5 (median: 4 weeks), weeks 6–8 (median: 7 weeks) and weeks
9–12 (median: 11.9 weeks). CTCs were determined with the
CellSearchTM (Menarini Silicon Biosystems) assay. Haemoglobin (Hb),
alkaline phosphatase (ALP), albumin and LDH concentrations were
obtained at baseline and at each study visit. Eastern Cooperative
Oncology Group (ECOG)-PS was obtained at baseline. PSA values were
obtained every 4weeks in IMMC-38 and every 12weeks in COU-AA-
301. Both studies were approved by local institutional boards. All patients
provided written informed consent.
Statistical analysis
Kaplan–Meier analysis was used to estimate overall survival. CTC pro-
gression was defined as any increase in CTC count relative to baseline at
either 4, 8 or 12weeks after treatment initiation. Uni- and multi-variable
Cox proportional hazards models were used to explore the association of
baseline CTC counts, CTC progression and CTC conversion (defined as
increase in CTCs from<5 to5), with survival. Baseline LDH, ALP, PSA
and CTCs, included as continuous variables, were log10-transformed due
to their positively skewed distribution. In order to include patients
with no detectable CTCs in the baseline count in the survival analyses,
which required log10 transformation, 0.1 was added to all the baseline
CTC counts. Logistic regressionmodels were used to compare differences
in PSA response and treatment arm by CTC progression and CTC
conversion status.
Cox-regression models constructed including a ‘Baseline’ model
(which included established clinical prognostic biomarkers: ECOG-PS,
LDH, PSA, Hb, ALP and albumin); a ‘Baseline CTC model’ (adding
baseline CTC counts to the ‘baseline model’) and a ‘CTC progression
Model’ (adding CTC progression to the ‘baseline CTC model’). A test
of proportionality based on the Schoenefeld residuals was applied to
evaluate the proportional hazards assumption (supplementary Figure
S2, available at Annals of Oncology online). The value of baseline
CTCs and of CTC progression was assessed by calculating Uno’s
inverse-probability weighted c-index and time-dependent incident
dynamic ROC area under the curve (AUC) values (with a 22-month
survival end point, which represents the median survival of the dataset)
of each of the models, according the method proposed by Blanche et al.
[15]. Bootstrapping was used to calculate the 95% confidence interval
(CI) and the difference (delta) between c-indices of each of the models
[16]. Analyses were carried out with SPSS v23 (SPSS Inc, IBM
Corporation, Armonk, New York, US) and the R statistics package
v3.4.0 (R Foundation).
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Results
Patient characteristics
Overall, a total of 511 patients participating in the COU-AA-301
(n¼ 421; 82.4%) and IMMC-38 (n¼ 90; 17.6%) clinical trials
met the selection criteria with baseline CTC counts< 5 cells/
7.5ml and were included in the analysis. Supplementary Figure
S1, available at Annals of Oncology online represents the Consort
Diagram with details of patients excluded from the analysis. An
analysis of patients with baseline CTC counts5 cells/7.5ml has
been published previously [10]. No major differences in baseline
patient characteristics were observed between IMMC-38 and
COU-AA-301 participants (Table 1). Median follow-up was
17.4months (range: 3.2–27.1months); 217 patients (43.6%) had
died at the time of analysis, 190 (45.3%) in COU-AA-301 and 27
(30%) in IMMC-38. Median overall survival was 21.98 (95% CI
20.7–23.3) months; there were no significant differences in sur-
vival between patients in the COU-AA-301 and IMMC-38 trials
(22.0 and 21.4months, respectively; P¼ 0.146).
Baseline CTC count and survival
Median baseline CTC count was 0 cells/7.5ml (0 cells/7.5ml in
both COU-AA-301 and IMMC-38). 259 patients (50.7%) had 0
CTCs at baseline; 212 (50.4%) in COU-301 and 47 (52.2%)
in IMMC-38. Baseline CTC count, as a log10-transformed
continuous variable, was associated with survival in these patients
overall [hazard ratio (HR) 1.65; 95% CI 1.32–2.05; P< 0.001],
and when analysing patients from COU-AA-301 (HR 1.57; 95%
CI: 1.25–1.96; P< 0.001) and IMMC-38 (1.98; 95% CI 1.09–3.61;
P¼ 0.026) separately. There was a significant linear trend in
survival when comparing patients with 0 (median 27.1months;
95% CI NR–NR), 1–2 (median 21.6months; 95% CI 19.7–23.5)
and 3–4 (median 15.1months; 95% CI 12.4–17.8) baseline CTCs
(P-value for linear trend¼ 0.001) (Figure 1).
CTC progression is associated with adverse
outcome
Overall, 213 (41.7%) patients experienced CTC progression in
the first 12 weeks of treatment; 184 (43.7%) in COU-AA-301 and
29 (32.2%) in IMMC-38; 117 (25.8%), 103 (23.8%) and 124
(24.4%) patients experienced CTC progression at 4, 8 and
12weeks, respectively. Patients experiencing CTC progression at
4weeks [23.8 versus 14.8months; HR 2.8 (95% CI 2.1–3.7);
P< 0.001], 8 weeks [24.1 versus 14.7months; HR 3.0 (95% CI
2.2–4); P< 0.001] and 12weeks [27.1 versus 13.6months; HR 3.9
(95% CI 2.9–5.2); P< 0.001] had significantly reduced survival
compared with those not experiencing CTC progression. At any
of the time-points, the association of CTC progression with
reduced survival was independent of other known prognostic
baseline characteristics. The impact of CTC progression was simi-
lar for both COU-AA-301 and IMMC-38 cohorts (Figure 2; sup-
plementary Table S1, available at Annals of Oncology online).
Similarly, the impact of CTC progression in multi-variable ana-
lysis (Table 2) was similar among patients with undetectable
[baseline CTC (BLCTC)¼ 0: HR 2.9 (95% CI 1.8–4.7);
P< 0.001] and detectable [BLCTC1: HR 3.5 (95% CI 2.4–5.1);
P< 0.001] counts (interaction test: P¼ 0.734).
To evaluate the added value of incorporating CTC
Progression for predicting survival, we constructed a survival
model incorporating baseline CTC counts and other prognos-
tic clinical variables and determined the survival models’ re-
ceiver operating characteristic (ROC) curve AUC and c-index.
The ROC curve AUC for the baseline model was 0.66 (95% CI
0.59–0.74). A non-significant increase to an AUC of 0.67 (95%
CI 0. 59–0.75) was observed when adding baseline CTC counts
to this baseline CTC model (P¼ 0.63). Adding CTC
Table 1. Baseline patient characteristics
All patients COU-301 Subset IMMC-38 Subset
N 511 421 90
BLCTC
0 259 (50.7%) 212 (50.4%) 47 (52.2%)
1–2 175 (34.3%) 146 (33.7%) 29 (32.2%)
3–4 77 (15.2%) 63 (16%) 14 (15.6%)
LDH (IU/L) 197.5 (167–233) 196 (167–230.8) 203 (167.8–247.3)
PSA (ng/mL) 71.6 (23.5–211.6) 69.6 (23–214.4) 79 (26.1–214.3)
Hb (g/dL) 12.5 (11.4–13.4) 12.4 (11.3–13.1) 13.2 (12.1–13.8)
ALP (IU/L) 87 (68–130) 86 (67–127.8) 96 (76–142)
Albumin (g/dL) 4.1 (3.8–4.3) 4.1 (3.9–4.4) 3.9 (3.6–4.3)
ECOG-PS
0–1 485 (95.3%) 401 (95.2%) 84 (93.3%)
2 24 (4.7%) 20 (4.8%) 4 (4.4%)
Abiraterone — 289 (68.6%) —
Placebo 132 (31.4%)
BLCTC, baseline circulating tumour cell; LDH, lactate dehydrogenase; PSA, prostate-speciﬁc antigen; Hb, haemoglobin; ALP, alkaline phosphatase; ECOG,
Eastern Cooperative Oncology Group.
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progression to the model substantially increased the ROC
AUC value (AUC 0.77; 95% CI 0.70–0.84) when compared
with the baseline CTC model (P< 0.001) (Figure 3). The
weighted c-index of the baseline model (0.682; SE: 0.023)
increased to 0.694 (SE: 0.026) after including baseline CTCs.
Inclusion of CTC progression in the model increased the
weighted c-index to 0.748 (SE: 0.019) (delta c-index¼ 0.056;
95% CI 0.025–0.087).
Overall, furthermore, 500 patients (98.2%) had data on PSA
response. PSA response, defined as a 50% decline from baseline,
was observed in 118 (28.2%) patients from COU-AA-301 and 42
(51.9%) patients from IMMC-38. Patients with CTC progression
had a significantly lower rate of PSA response than those without
CTC progression [11.4% versus 47.1%; odds ratio (OR) 0.14
(95% CI 0.09–0.23), P< 0.001]; similar associations were
observed in the COU-AA-301 [OR 0.14 (95% CI 0.08–0.24);
P< 0.001] and IMMC-38 [OR 0.17 (95% CI 0.06–0.48);
P¼ 0.001] patient subsets (supplementary Table S2, available at
Annals of Oncology online).
Comparing CTC progression and CTC conversion
Overall, 90 patients (17.7%) experienced a conversion to un-
favourable (5 CTCs/7.5mL) counts during the first 12-weeks of
treatment; 76 (18.1%) in the COU-AA-301 and 14 (15.6%) in the
IMMC-38 trials. A CTC conversion was associated with a worse
outcome (23.8 vs 10months; HR: 3.78 [95%CI: 2.82-5.06];
p< 0.001) in both uni- and multi-variable Cox-regression mod-
els (supplementary Table S3, available at Annals of Oncology on-
line), as well as a reduced PSA response rate (OR 0.08 [95%CI:
0.03-0.2]; p< 0.001); only 4 (4.4%) patients with a CTC conver-
sion experienced a PSA response (supplementary Table S2, avail-
able at Annals of Oncology online).
The weighted c-index of the model including CTC progression
was significantly higher than that of the model including CTC
conversion (0.750 vs 0.705; delta c-index: 0.045 [95%CI: 0.019-
0.071]). The ROC curve AUC index was also significantly higher
for CTC progression than for CTC conversions (0.77 vs 0.69;
95% CI: 0.61-0.76; p< 0.001) (supplementary Figure S3, avail-
able at Annals of Oncology online).
CTC progression in COU-AA-301: Interaction with
treatment arm
Overall, 419 patients participating in the COU-AA-301 trial
were included in this analysis, 288 (68.7%) receiving abiratero-
neþ prednisone and 131 (31.3%) placeboþ prednisone. There
was no significant difference in survival between these cohorts
(HR 0.86; 95% CI 0.63–1.17; P¼ 0.330). CTC progression was
more frequent in the placebo (68 patients, 51.9%) arm than in
the abiraterone (115 patients, 39.9%) arm (OR 0.6; P¼ 0.022).
The survival decrease in patients experiencing CTC progression
was similar in the abiraterone (24.1 versus 15.1months; HR 3.76;
P< 0.001) and placebo arms (NR versus 13.8months; HR 3.23;
P< 0.001). The interaction test between treatment arm and CTC
progression was not significant (P¼ 0.952), indicating that the
impact of CTC progression on survival was similar for patients in
both trial arms.
Discussion
Improvements in the development of predictive biomarkers for
advanced prostate cancer care including AR splice variants and
AR genomic aberrations for novel hormonal agents; DNA repair
aberrations for PARP inhibitors and PTEN loss for agents target-
ing the PI3K/AKT pathway are anticipated in the future [17]. The
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development of response biomarkers to rapidly identify resistant
disease and guide early treatment switches remains, however, an
unmet clinical need. The value of circulating tumour cells as a
prognostic indicator for advanced prostate cancer care has been
well described [8, 9, 13]. Because of regulatory concerns about
assay performance when CTCs are low, patients have been cate-
gorized into unfavourable (CTCs 5/7.5ml) and favourable
CTC count groups, which have distinct prognoses. The value of
CTCs as an indicator of clinical activity has also been reported:
post-treatment CTC declines, either as a fold-decline, 30% de-
cline or conversion to favourable counts have all been associated
with improved survival in the subgroup of patients with un-
favourable baseline CTC counts [7, 10, 12]. PCWG3 now recom-
mends the use of CTCs as an end point for activity in patients
with unfavourable counts at baseline in the setting of clinical tri-
als [2]. This approach, however, captures only approximately
50% of patients (with unfavourable baseline counts) as assessable
and classifies those with favourable baseline counts as non-assess-
able for response.
The role of increasing CTC counts as an indicator of disease
progression has been less well studied. We present what is, to our
knowledge, the largest dataset analysing the role of increasing
CTCs as a biomarker of progression analysing exclusively patients
with low (<5) baseline CTC counts at baseline, treated with AR
targeting agents (COU-AA-301) and chemotherapy (IMMC-38)
in each of the prospective clinical trials. In our study, CTC pro-
gression (defined as any increase in CTC counts) and ‘CTC con-
versions’ (defined as an increase to at least 5 CTCs/7.5ml) during
the first 12 weeks of treatment are associated with a worse out-
come in patients treated with either abiraterone or chemother-
apy. Furthermore, CTC progression increased the power of the
survival model that included key clinical variables and baseline
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CTCs.We show that CTC progression is superior to CTC conver-
sion as a biomarker of poor overall survival with superior model
performance as defined by ROC AUC values and c-indices. This
is in line with our previous conclusions in patients with un-
favourable CTC counts, where failure to effectively reduce CTCs
(‘stable’ CTC counts) had a similar adverse impact to primary
‘progressing’ CTC counts [10]. Recently, Heller et al. [18] pre-
sented a pooled analysis of five randomized mCRPC trials, where
both a CTC conversion (5 CTCs to< 5CTCs) and a CTC0 end
point (>1 CTCs to 0 CTCs) had a higher discriminatory value
(c-index) than commonly used PSA end points. CTC0 end points
were able to evaluate a significantly higher number of patients
than CTC conversion end points. In patients with treatment
naive mCRPC (ELM-PC-4 trial), however, as many as 33% and
61% of patients were non-assessable for CTC0 (due to baseline 0
CTC) and CTC conversion (due to baseline< 5 CTCs), respect-
ively [18]. An approach incorporating CTC increase end points
for patients with low baseline CTC counts could therefore render
all patients assessable for CTC efficacy end points.
A number of limitations to our study should, however, be
acknowledged: (i) its unplanned, post hoc nature (ii) not all
patients enrolled in COU-AA-301 had CTCs (CTCs were col-
lected in 858 of 1195 [71.8%] patients), which could have led to a
selection bias; (iii) the unavailability of CTC counts beyond 12
weeks in COU-AA-301, with our results therefore not being ap-
plicable to CTC counts beyond that time-point; (iv) the fact that
patients treated in COU-AA-301 were over fourfold more nu-
merous than those in IMMC-38 and (v) LDH kinetics were not
incorporated into the analyses.
In conclusion, these data indicate that CTC progression in the
first 12 weeks of chemotherapy or endocrine therapy can identify
patients with low baseline CTC counts (<5) not benefiting from
treatment. These data have significant clinical and health eco-
nomic implications and could guide the response assessment of
patients during the first 12 weeks of treatment, identifying early
disease progression, and could be used as efficacy biomarkers in
clinical trials. Prospective phase III trials are now needed to valid-
ate these findings, and confirm the clinical utility of CTCs [9].
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